Ondine Biomedical Inc.
OBIMF
$0.11
-$0.02-15.39%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.21M | 1.05M | 891.20K | 744.90K | 600.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.21M | 1.05M | 891.20K | 744.90K | 600.10K |
| Cost of Revenue | 482.10K | 427.40K | 370.40K | 337.50K | 306.40K |
| Gross Profit | 724.10K | 624.20K | 520.80K | 407.40K | 293.70K |
| SG&A Expenses | 6.48M | 6.89M | 7.26M | 8.23M | 9.28M |
| Depreciation & Amortization | 404.60K | 414.60K | 422.40K | 408.30K | 396.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.99M | 11.96M | 11.86M | 13.04M | 14.34M |
| Operating Income | -10.78M | -10.91M | -10.97M | -12.30M | -13.74M |
| Income Before Tax | -10.54M | -10.64M | -10.68M | -12.27M | -13.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.54 | -10.64 | -10.68 | -12.27 | -13.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.54M | -10.64M | -10.68M | -12.27M | -13.98M |
| EBIT | -10.78M | -10.91M | -10.97M | -12.30M | -13.74M |
| EBITDA | -10.64M | -10.76M | -10.82M | -12.14M | -13.58M |
| EPS Basic | -0.04 | -0.05 | -0.05 | -0.06 | -0.07 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| EPS Diluted | -0.04 | -0.05 | -0.05 | -0.06 | -0.07 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 936.45M | 889.69M | 842.94M | 810.78M | 778.62M |
| Average Diluted Shares Outstanding | 936.45M | 889.69M | 842.94M | 810.78M | 778.62M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
